On October 24, 2024 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that the results of non-clinical research on SAIL66, a Chugai’s in-house project under Phase I clinical development for CLDN6 positive solid tumors, have been published in the Journal for ImmunoTherapy of Cancer (Press release, Chugai, OCT 24, 2024, View Source [SID1234647362]). The journal is a renowned academic journal in the field of cancer immunotherapy, published by the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) in the United States.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137"
(View Source)
The following findings were demonstrated in this research, which suggest that SAIL66 may be useful as a treatment for CLDN6 positive solid tumors.
Creation of SAIL66, which is a novel tri-specific T-cell engager* (TCE) for Claudin-6 (CLDN6), CD3, and CD137, applying Dual-Ig technology, Chugai’s proprietary antibody engineering technology
*T-cell engager: A therapeutic agent that exerts anti-tumor effects by bringing T cells, which are immune cells, closer to tumor cells
SAIL66 binds to CLDN6, which is specifically expressed on tumor tissue, and does not bind to other CLDN family proteins (CLDN3, 4, or 9) with similar amino sequences
in vitro, SAIL66 was shown to strongly activate T cells and exert cancer cell cytotoxicity by not only triggering CD3 signaling like conventional TCEs, but also by providing CD137 co-stimulation
In experiments using mice, SAIL66 was shown to increase intratumor T-cells and decrease the number of exhausted T cells, leading to enhanced antitumor efficacy compared to conventional TCEs
About SAIL66
SAIL66 is an anti-CLDN6/CD3/CD137 trispecific antibody and one of the next-generation T-cell engagers (TCEs) applying Chugai’s proprietary Dual-Ig technology. Conventional TCEs are designed to guide T cells to the target cancer cells by activating and engaging T cells through its binding to CD3 on T cells. Dual-Ig technology is a novel technology providing antibodies with the ability to induce CD137 signaling, a co-stimulating molecule, in addition to CD3 signaling. This property enables to maintain T cell activity, potentially inducing more potent antitumor effects than conventional T-cell engagers.